Somerset Therapeutics, LLC announced the September 13, 2024 approval of its and for prochlorperazine edisylate, signalling a robust pipeline that positions the company to meet a significant unmet medical need. This market entrant establishes an important competitive alternative in the intramuscular treatment space, along with expanding Somerset's portfolio in the generic pharmaceutical sector.